• Home
  1. Home
  2. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma
Scientific article
English

Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma

ContributorsAlgazi, Alain P; Twitty, Christopher G; Tsai, Katy K; Le, Mai; Pierce, Robert; Browning, Erica; Hermiz, Reneta; Canton, David A; Bannavong, Donna; Oglesby, Arielle; Francisco, Murray; Fong, Lawrence; Pittet, Mikaëlorcid; Arlauckas, Sean P; Garris, Christopher; Levine, Lauren P; Bifulco, Carlos; Ballesteros-Merino, Carmen; Bhatia, Shailender; Gargosky, Sharron; Andtbacka, Robert H I; Fox, Bernard A; Rosenblum, Michael D; Daud, Adil I
Published inClinical Cancer Research, vol. 26, no. 12, p. 2827-2837
Publication date2020
Abstract

Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; "tavo") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).

Affiliation entities Not a UNIGE publication
Research groups
Citation (ISO format)
ALGAZI, Alain P et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. In: Clinical Cancer Research, 2020, vol. 26, n° 12, p. 2827–2837. doi: 10.1158/1078-0432.CCR-19-2217
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN1078-0432
219views
0downloads

Technical informations

Creation08/07/2021 17:05:00
First validation08/07/2021 17:05:00
Update time16/03/2023 01:05:16
Status update16/03/2023 01:05:15
Last indexation07/10/2025 09:25:24
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack